C WorldWide Group Holding A S Has $2.73 Million Position in Cempra, Inc. (CEMP)
C WorldWide Group Holding A S cut its stake in shares of Cempra, Inc. (NASDAQ:CEMP) by 9.5% during the second quarter, Holdings Channel reports. The firm owned 592,946 shares of the biotechnology company’s stock after selling 61,965 shares during the period. C WorldWide Group Holding A S’s holdings in Cempra were worth $2,728,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of CEMP. State Street Corp raised its position in Cempra by 85.8% in the fourth quarter. State Street Corp now owns 2,133,275 shares of the biotechnology company’s stock valued at $5,973,000 after buying an additional 985,427 shares during the period. Renaissance Technologies LLC bought a new position in Cempra during the fourth quarter valued at about $1,711,000. Guggenheim Capital LLC bought a new position in Cempra during the fourth quarter valued at about $560,000. Norges Bank bought a new position in Cempra during the fourth quarter valued at about $743,000. Finally, Teachers Advisors LLC raised its position in Cempra by 5.2% in the fourth quarter. Teachers Advisors LLC now owns 93,481 shares of the biotechnology company’s stock valued at $262,000 after buying an additional 4,632 shares during the period. Institutional investors own 52.28% of the company’s stock.
Shares of Cempra, Inc. (CEMP) opened at 3.20 on Friday. The stock’s market cap is $167.99 million. The company has a 50-day moving average price of $4.17 and a 200-day moving average price of $3.83. Cempra, Inc. has a 12 month low of $2.55 and a 12 month high of $26.95.
Cempra (NASDAQ:CEMP) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.09. The firm had revenue of $0.86 million for the quarter, compared to the consensus estimate of $3.58 million. Cempra had a negative return on equity of 53.99% and a negative net margin of 560.40%. The firm’s quarterly revenue was down 74.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.51) EPS. On average, analysts expect that Cempra, Inc. will post ($1.00) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “C WorldWide Group Holding A S Has $2.73 Million Position in Cempra, Inc. (CEMP)” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.watchlistnews.com/c-worldwide-group-holding-a-s-has-2-73-million-position-in-cempra-inc-cemp/1478006.html.
Several equities analysts have issued reports on CEMP shares. Vetr upgraded Cempra from a “buy” rating to a “strong-buy” rating and set a $4.86 target price on the stock in a research note on Monday, May 1st. Zacks Investment Research upgraded Cempra from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research note on Tuesday, May 2nd. Jefferies Group LLC reiterated a “hold” rating and issued a $3.00 target price on shares of Cempra in a research note on Thursday, May 25th. ValuEngine lowered Cempra from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $4.00 target price on shares of Cempra in a research note on Thursday. Four investment analysts have rated the stock with a sell rating, eleven have given a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $11.38.
Cempra Company Profile
Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).
Want to see what other hedge funds are holding CEMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cempra, Inc. (NASDAQ:CEMP).
Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.